John F. Seymour

54.4k total citations · 13 hit papers
561 papers, 23.8k citations indexed

About

John F. Seymour is a scholar working on Genetics, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, John F. Seymour has authored 561 papers receiving a total of 23.8k indexed citations (citations by other indexed papers that have themselves been cited), including 315 papers in Genetics, 278 papers in Pathology and Forensic Medicine and 166 papers in Oncology. Recurrent topics in John F. Seymour's work include Lymphoma Diagnosis and Treatment (276 papers), Chronic Lymphocytic Leukemia Research (266 papers) and Acute Myeloid Leukemia Research (73 papers). John F. Seymour is often cited by papers focused on Lymphoma Diagnosis and Treatment (276 papers), Chronic Lymphocytic Leukemia Research (266 papers) and Acute Myeloid Leukemia Research (73 papers). John F. Seymour collaborates with scholars based in Australia, United States and United Kingdom. John F. Seymour's co-authors include Andrew W. Roberts, Jeffrey Presneill, H. Miles Prince, Thomas J. Kipps, Chan Y. Cheah, Andrew Grigg, Pierre Fenaux, Mary Ann Anderson, Valeria Santini and Alan F. List and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

John F. Seymour

535 papers receiving 23.3k citations

Hit Papers

Efficacy of azacitidine compared with that of conventiona... 2003 2026 2010 2018 2009 2015 2018 2009 2011 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
    2009 1.8k citations Pierre Fenaux, Ghulam J. Mufti et al. profile →
  2. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
    2015 1.3k citations Andrew W. Roberts, Matthew S. Davids et al. New England Journal of Medicine profile →
  3. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
    2018 971 citations John F. Seymour, Thomas J. Kipps et al. Blood profile →
  4. Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia
    2009 698 citations Pierre Fenaux, Ghulam J. Mufti et al. Journal of Clinical Oncology profile →
  5. Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease
    2011 632 citations Andrew W. Roberts, John F. Seymour et al. Journal of Clinical Oncology profile →
  6. Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
    2018 595 citations John F. Seymour, Thomas J. Kipps et al. New England Journal of Medicine profile →
  7. Report of an International Workshop to Standardize Baseline Evaluation and Response Criteria for Primary CNS Lymphoma
    2005 582 citations John F. Seymour et al. Journal of Clinical Oncology profile →
  8. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis
    2003 561 citations Andrew Grigg, Jeff Szer et al. Blood profile →
  9. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
    2013 508 citations John F. Seymour, Andrew Grigg et al. Blood profile →
  10. Obinutuzumab for the First-Line Treatment of Follicular Lymphoma
    2017 461 citations Robert Marcus, Stephen Opat et al. New England Journal of Medicine profile →
  11. Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia
    2018 276 citations Piers Blombery, Mary Ann Anderson et al. Cancer Discovery profile →
  12. Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma
    2018 274 citations Constantine S. Tam, Mary Ann Anderson et al. New England Journal of Medicine profile →
  13. Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia
    2025 21 citations Jennifer R. Brown, John F. Seymour et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John F. Seymour Australia 74 10.7k 9.8k 7.9k 6.8k 5.1k 561 23.8k
Wolfgang Hiddemann Germany 79 6.9k 0.6× 9.8k 1.0× 11.0k 1.4× 9.3k 1.4× 8.1k 1.6× 644 27.2k
Thomas E. Witzig United States 101 8.6k 0.8× 14.1k 1.4× 9.6k 1.2× 13.5k 2.0× 11.2k 2.2× 778 34.1k
Alessandro Rambaldi Italy 83 8.5k 0.8× 4.7k 0.5× 9.6k 1.2× 5.6k 0.8× 8.1k 1.6× 661 24.3k
David C. Linch United Kingdom 74 4.9k 0.5× 6.6k 0.7× 8.9k 1.1× 7.0k 1.0× 4.8k 0.9× 358 20.9k
Jamés O. Armitage United States 74 6.2k 0.6× 15.9k 1.6× 4.3k 0.5× 12.4k 1.8× 2.5k 0.5× 487 25.6k
Julie M. Vose United States 71 6.9k 0.6× 19.0k 1.9× 3.2k 0.4× 13.1k 1.9× 2.7k 0.5× 460 25.3k
Fernando Cabanillas United States 77 7.5k 0.7× 18.1k 1.8× 2.8k 0.4× 12.9k 1.9× 2.7k 0.5× 470 25.9k
Hanneke C. Kluin‐Nelemans Netherlands 63 4.2k 0.4× 6.5k 0.7× 3.2k 0.4× 4.5k 0.7× 2.1k 0.4× 376 14.0k
Susan O’Brien United States 100 17.3k 1.6× 8.4k 0.9× 21.3k 2.7× 7.4k 1.1× 8.3k 1.6× 840 36.5k
Stephen M. Ansell United States 83 5.6k 0.5× 13.8k 1.4× 2.9k 0.4× 15.0k 2.2× 4.2k 0.8× 741 26.6k

Countries citing papers authored by John F. Seymour

Since Specialization
Citations

This map shows the geographic impact of John F. Seymour's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John F. Seymour with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John F. Seymour more than expected).

Fields of papers citing papers by John F. Seymour

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John F. Seymour. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John F. Seymour. The network helps show where John F. Seymour may publish in the future.

Co-authorship network of co-authors of John F. Seymour

This figure shows the co-authorship network connecting the top 25 collaborators of John F. Seymour. A scholar is included among the top collaborators of John F. Seymour based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John F. Seymour. John F. Seymour is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Brown, Jennifer R., John F. Seymour, Wojciech Jurczak, et al.. (2025). Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia. New England Journal of Medicine. 392(8). 748–762. 21 indexed citations breakdown →
3.
Cheah, Chan Y. & John F. Seymour. (2023). Marginal zone lymphoma: 2023 update on diagnosis and management. American Journal of Hematology. 98(10). 1645–1657. 15 indexed citations
4.
Odutola, Michael K., Marina T. van Leeuwen, Fiona Bruinsma, et al.. (2023). Occupational exposure to extremely low-frequency magnetic fields and follicular lymphoma risk: a family case–control study. Occupational and Environmental Medicine. 80(10). 599–602.
5.
Jain, Nitin, Lisa J. Croner, John N. Allan, et al.. (2023). Absence of BTK , BCL2 , and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax. Clinical Cancer Research. 30(3). 498–505. 20 indexed citations
6.
Townsend, William, Wolfgang Hiddemann, Christian Buske, et al.. (2023). Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study. HemaSphere. 7(7). e919–e919. 27 indexed citations
7.
Davids, Matthew S., Andrew W. Roberts, Vaishalee P. Kenkre, et al.. (2021). Long-term Follow-up of Patients with Relapsed or Refractory Non–Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study. Clinical Cancer Research. 27(17). 4690–4695. 48 indexed citations
8.
Lew, Thomas E., Mary Ann Anderson, Victor S. Lin, et al.. (2020). Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months. Blood Advances. 4(1). 165–173. 31 indexed citations
9.
Borromeo, Gelsomina L., Claudine Tsao, Michael S. Hofman, et al.. (2020). Teriparatide Promotes Bone Healing in Medication-Related Osteonecrosis of the Jaw: A Placebo-Controlled, Randomized Trial. Journal of Clinical Oncology. 38(26). 2971–2980. 86 indexed citations
10.
Doo, Nicole Wong, Victoria White, Kara Martin, et al.. (2019). The Use of Optimal Treatment for DLBCL Is Improving in All Age Groups and Is a Key Factor in Overall Survival, but Non-Clinical Factors Influence Treatment. Cancers. 11(7). 928–928. 4 indexed citations
11.
Blombery, Piers, Mary Ann Anderson, Jianan Gong, et al.. (2018). Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia. Cancer Discovery. 9(3). 342–353. 276 indexed citations breakdown →
12.
MacManus, Michael, Richard Fisher, Daniel Roos, et al.. (2018). Randomized Trial of Systemic Therapy After Involved-Field Radiotherapy in Patients With Early-Stage Follicular Lymphoma: TROG 99.03. Journal of Clinical Oncology. 36(29). 2918–2925. 66 indexed citations
13.
Hiddemann, Wolfgang, Anna Maria Barbui, Miguel Canales, et al.. (2018). Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety. Journal of Clinical Oncology. 36(23). 2395–2404. 144 indexed citations
14.
Anderson, Mary Ann, Jing Deng, John F. Seymour, et al.. (2016). The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. Blood. 127(25). 3215–3224. 215 indexed citations
15.
Roberts, Andrew W., Matthew S. Davids, John M. Pagel, et al.. (2015). Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. New England Journal of Medicine. 374(4). 311–322. 1337 indexed citations breakdown →
16.
Lingaratnam, Senthil, Monica A. Slavin, Bogda Koczwara, et al.. (2011). Introduction to the Australian consensus guidelines for the management of neutropenic fever in adult cancer patients, 2010/2011. Internal Medicine Journal. 41(1b). 75–81. 29 indexed citations
17.
Wheeler, Greg, et al.. (2009). Challenges Facing Survivors of Childhood and Adolescent Cancer. Cancer Forum. 33(3). 188. 2 indexed citations
18.
Fenaux, Pierre, Ghulam J. Mufti, Eva Hellström‐Lindberg, et al.. (2009). Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia. Journal of Clinical Oncology. 28(4). 562–569. 698 indexed citations breakdown →
19.
Seymour, John F., Jeffrey Presneill, Otto D. Schoch, et al.. (2001). Therapeutic Efficacy of Granulocyte-Macrophage Colony-Stimulating Factor in Patients with Idiopathic Acquired Alveolar Proteinosis. American Journal of Respiratory and Critical Care Medicine. 163(2). 524–531. 157 indexed citations
20.
Seymour, John F.. (1979). Guía práctica ilustrada para la vida en el campo.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Wolfgang Hiddemann Breakdown of academic impact, for papers by Thomas E. Witzig Breakdown of academic impact, for papers by Alessandro Rambaldi Breakdown of academic impact, for papers by David C. Linch Breakdown of academic impact, for papers by Jamés O. Armitage Breakdown of academic impact, for papers by Julie M. Vose Breakdown of academic impact, for papers by Fernando Cabanillas Breakdown of academic impact, for papers by Hanneke C. Kluin‐Nelemans Breakdown of academic impact, for papers by Susan O’Brien Breakdown of academic impact, for papers by Stephen M. Ansell
Rankless by CCL
2026